Skip to main content
. 2021 Jan 27;15:339–347. doi: 10.2147/DDDT.S286529

Table 2.

Short-Term Efficacy of Anlotinib Monotherapy

Short-Term Efficacy Number of Patients (Percent)
Complete response (CR) 0 (0%)
Partial response (PR) 4 (23.5%)
Stable disease (SD) 10 (58.8%)
Progressive disease (PD) 3 (17.6%)

Note: Short-term efficacy was classified by modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).